Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05204888 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 18 to 27v10
  2. Study sites revised (18)v9
  3. Study sites: 12 to 18v8
  4. Study sites: 9 to 12v7
  5. Study sites: 3 to 9
    • Eligibility criteria expanded, about 61 words
    • Collaborator revised
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Eligibility criteria expanded, about 30 wordsv5
  2. Study sites: 1 to 3v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v3
  4. Start date: Jan 2022 to Feb 2, 2022
    • Eligibility criteria expanded, about 1 word
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Temple University
44 trials monitored
See 2 trials at risk
COPD
1,119 trials monitored
See 34 trials at risk
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.
Trial Details
NCT Number NCT05204888
Lead Sponsor Temple University
Collaborators: Fisher and Paykel Healthcare
Conditions
(from sponsor)		 COPD
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 642 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov